Washington, D.C. – October 27, 2015 – The Center for Lawful Access and Abuse Deterrence (CLAAD) will participate in the Second Human Abuse Liability and Abuse-Deterrent Formulations Conference next Wednesday in Bethesda, Maryland. CLAAD’s presentation Defining the Next Generation of Abuse Deterrent Techniques will discuss abuse-deterrent technologies currently recognized by the FDA, as well as novel delivery systems, low-residual-dose technologies, and other next-generation concepts of abuse deterrence. This presentation calls for a forward-thinking expansion of the definition of abuse-deterrent medications to encourage widespread adoption throughout the market.
“CLAAD is pleased to participate in the Human Abuse Liability and Abuse-Deterrent Formulations conference,” said Michael Barnes, Executive Director of CLAAD. “The event will provide an important forum for collaboration toward expanding the use of abuse-deterrent medications as a tool to reduce prescription drug diversion, misuse, abuse and accidental exposure.”
The conference will take place on November 2 and 3, at the Hyatt Regency in Bethesda, Maryland. Follow the link for more information on the conference or to register: http://bit.ly/1iEO9ol.